Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Inventiva reports its 2024 full year results and provides a business updateGlobeNewswire
- Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial ResultsGlobeNewswire
- Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatmentGlobeNewswire
- Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trialGlobeNewswire
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business updateGlobeNewswire
IVA
Analyst Actions
- 1/30/25 - HC Wainwright
IVA
Sec Filings
- 3/26/25 - Form SCHEDULE
- 3/26/25 - Form 6-K
- 2/20/25 - Form 6-K
- IVA's page on the SEC website